Growth Metrics

Kiniksa Pharmaceuticals International (KNSA) Total Non-Current Liabilities (2021 - 2025)

Historic Total Non-Current Liabilities for Kiniksa Pharmaceuticals International (KNSA) over the last 5 years, with Q3 2025 value amounting to $162.4 million.

  • Kiniksa Pharmaceuticals International's Total Non-Current Liabilities rose 3962.43% to $162.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was $162.4 million, marking a year-over-year increase of 3962.43%. This contributed to the annual value of $140.3 million for FY2024, which is 6384.7% up from last year.
  • As of Q3 2025, Kiniksa Pharmaceuticals International's Total Non-Current Liabilities stood at $162.4 million, which was up 3962.43% from $156.9 million recorded in Q2 2025.
  • Kiniksa Pharmaceuticals International's 5-year Total Non-Current Liabilities high stood at $162.4 million for Q3 2025, and its period low was $37.9 million during Q3 2021.
  • Over the past 5 years, Kiniksa Pharmaceuticals International's median Total Non-Current Liabilities value was $74.1 million (recorded in 2022), while the average stood at $84.8 million.
  • Per our database at Business Quant, Kiniksa Pharmaceuticals International's Total Non-Current Liabilities soared by 9544.64% in 2022 and then crashed by 2105.04% in 2023.
  • Over the past 5 years, Kiniksa Pharmaceuticals International's Total Non-Current Liabilities (Quarter) stood at $47.5 million in 2021, then grew by 29.88% to $61.7 million in 2022, then surged by 38.81% to $85.6 million in 2023, then skyrocketed by 63.85% to $140.3 million in 2024, then rose by 15.77% to $162.4 million in 2025.
  • Its last three reported values are $162.4 million in Q3 2025, $156.9 million for Q2 2025, and $136.7 million during Q1 2025.